Literature DB >> 1363080

Ocular side effects of selected systemic drugs.

S D Jaanus.   

Abstract

Numerous systemic drugs produce adverse effects that involve the eye. Pigmentary inclusions of the lids or conjunctivae or both may be caused by a variety of drugs, including amiodarone, chlorpromazine, and gold salts, while conjunctivitis and blepharoconjunctivitis have been associated with isotretinoin, sulfonamides, salicylates, and antineoplastic agents. Dry eye complaints may be caused by antihistamines, beta-receptor blocking agents prescribed for cardiovascular problems, antianxiety agents, and tricyclic antidepressants. Several drugs have been well documented as causes of keratopathies and/or lenticular deposits, including chloroquine and hydroxychloroquine, chlorpromazine, gold salts, systemic corticosteroids, nonsteroidal antiinflammatory drugs, and the antiarrhythmic agent amiodarone. Visual acuity may be decreased by transient changes in refractive error caused by sulfonamides, the antifungal agent metronidazole, thiazide diuretics, and carbonic anhydrase inhibitors. Dilation of the pupil may be caused by anticholinergic drugs, antihistamines, antidepressant agents, and central nervous system stimulants such as cocaine, methylphenidate, and amphetamines. Nystagmus, diplopia, and extraocular muscle palsies have been associated with central nervous system depressants, antihistamines, barbiturates, and elevated blood ethanol concentrations. Intraocular pressure can be elevated in susceptible individuals by long-term use of topical or systemic corticosteroids. Numerous drugs have been associated with retinal toxicity, including chloroquine and hydroxychloroquine, thioridazine, tamoxifen, and talc, which may embolize to the retinal circulation when administered by long-term drug abusers. The antituberculosis agents ethambutol and isoniazid have been implicated as causes of reduced acuity, visual field defects, and disturbances of color vision. Optic neuritis and retrobulbar neuritis may result from the use of chloramphenicol. This paper describes these and other adverse ocular effects that may be encountered when examining patients who are taking systemic drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1363080

Source DB:  PubMed          Journal:  Optom Clin        ISSN: 1050-6918


  14 in total

Review 1.  Phase I and phase II ocular metabolic activities and the role of metabolism in ophthalmic prodrug and codrug design and delivery.

Authors:  Abeer M Al-Ghananeem; Peter A Crooks
Journal:  Molecules       Date:  2007-03-08       Impact factor: 4.411

Review 2.  The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland.

Authors:  Erich Knop; Nadja Knop; Thomas Millar; Hiroto Obata; David A Sullivan
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

3.  Predicting chemical ocular toxicity using a combinatorial QSAR approach.

Authors:  Renee Solimeo; Jun Zhang; Marlene Kim; Alexander Sedykh; Hao Zhu
Journal:  Chem Res Toxicol       Date:  2012-11-19       Impact factor: 3.739

Review 4.  Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Yoshihiro Inamoto; Igor Petriček; Linda Burns; Saurabh Chhabra; Zachariah DeFilipp; Peiman Hematti; Alicia Rovó; Raquel Schears; Ami Shah; Vaibhav Agrawal; Aisha Ahmed; Ibrahim Ahmed; Asim Ali; Mahmoud Aljurf; Hassan Alkhateeb; Amer Beitinjaneh; Neel Bhatt; Dave Buchbinder; Michael Byrne; Natalie Callander; Kristina Fahnehjelm; Nosha Farhadfar; Robert Peter Gale; Siddhartha Ganguly; Shahrukh Hashmi; Gerhard C Hildebrandt; Erich Horn; Ann Jakubowski; Rammurti T Kamble; Jason Law; Catherine Lee; Sunita Nathan; Olaf Penack; Ravi Pingali; Pinki Prasad; Drazen Pulanic; Seth Rotz; Aditya Shreenivas; Amir Steinberg; Khalid Tabbara; André Tichelli; Baldeep Wirk; Jean Yared; Grzegorz W Basak; Minoo Battiwalla; Rafael Duarte; Bipin N Savani; Mary E D Flowers; Bronwen E Shaw; Nuria Valdés-Sanz
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-03       Impact factor: 5.742

Review 5.  Ocular barriers as a double-edged sword: preventing and facilitating drug delivery to the retina.

Authors:  Lixiang Wang; Hui Zhang
Journal:  Drug Deliv Transl Res       Date:  2022-09-21       Impact factor: 5.671

6.  Differential diagnosis of optic neuritis in a patient with ankylosing spondylitis.

Authors:  Simone Appenzeller; Gláucio R Werner de Castro; Percival D Sampaio-Barros; Zoraida Sachetto; Adil M Samara; Sandra Regina M Fernandes
Journal:  Rheumatol Int       Date:  2003-10-31       Impact factor: 2.631

7.  Long-term Natural History of Dry Eye Disease from the Patient's Perspective.

Authors:  Jeffrey P Lienert; Laura Tarko; Miki Uchino; William G Christen; Debra A Schaumberg
Journal:  Ophthalmology       Date:  2015-11-21       Impact factor: 12.079

8.  Testing for benzodiazepine inebriation--relationship between benzodiazepine concentration and simple clinical tests for impairment in a sample of drugged drivers.

Authors:  Jørgen G Bramness; Svetlana Skurtveit; Jørg Mørland
Journal:  Eur J Clin Pharmacol       Date:  2003-09-20       Impact factor: 2.953

9.  Drug therapy of attention deficit hyperactivity disorder: current trends.

Authors:  Avinash De Sousa; Gurvinder Kalra
Journal:  Mens Sana Monogr       Date:  2012-01

10.  Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.

Authors:  E R Samuels; E Szabadi
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.